Decision-Making and Quality of Life Surrounding Hematologic Disease and Gene Therapy

Plain-language summary

This study explores decision-making and quality of life among patients (and their families) who are eligible for gene therapy to treat a blood (hematologic) disease. Adults aged 18 and over eligible for gene therapy, or parents of eligible pediatric patients, may take part. It is a non-phase study that is enrolling by invitation.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Enrolling by invitation

Sponsor

Georgetown University

Start date

10/1/2024

Estimated completion

12/1/2026

Countries

United States

Related genes

Locations

• Washington D.C., United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* adult patients (ages 18+) or parents of pediatric patients (\<age 18) eligible to receive treatment for their disease with gene therapy

Exclusion Criteria:

* Non-English-speaking